Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GenSciP153
- Development stage
- Preclinical
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
`GenSciP153` (also known as `GenSci153`) is an investigational Actinium-225 ($^{225}\text{Ac}$)-labeled radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA). Developed by Changchun GeneScience Pharmaceutical, a subsidiary of Changchun High-Tech, the drug is designed for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). By binding selectively to PSMA-expressing tumor cells, GenSciP153 delivers high-energy alpha-particle radiation directly to the tumor site, inducing DNA double-strand breaks and tumor cell death while minimizing damage to surrounding healthy tissues. The candidate is currently in IND-enabling development, with investigator-initiated trials (IIT) planned or ongoing.
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on GenSciP153.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenSciP153.